Robert W. Baird Lowers Boston Scientific (NYSE:BSX) Price Target to $75.00

Boston Scientific (NYSE:BSX) had its price target lowered by equities research analysts at Robert W. Baird from $78.00 to $75.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has an “outperform” rating on the medical equipment provider’s stock. Robert W. Baird’s price target indicates a potential upside of 34.26% from the stock’s previous close.

A number of other equities research analysts have also recently commented on BSX. Needham & Company LLC reiterated a “buy” rating and set a $77.00 target price on shares of Boston Scientific in a report on Monday. Jefferies Financial Group reduced their price objective on Boston Scientific from $110.00 to $100.00 and set a “buy” rating on the stock in a research report on Wednesday, April 22nd. Royal Bank Of Canada decreased their price objective on Boston Scientific from $105.00 to $100.00 and set an “outperform” rating on the stock in a research note on Thursday, April 23rd. Morgan Stanley dropped their price objective on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Finally, Weiss Ratings downgraded shares of Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $92.71.

Boston Scientific Stock Performance

Shares of BSX opened at $55.86 on Tuesday. Boston Scientific has a 12-month low of $52.52 and a 12-month high of $109.50. The stock has a market cap of $83.02 billion, a P/E ratio of 23.37, a PEG ratio of 0.97 and a beta of 0.62. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The company has a 50-day moving average of $63.06 and a two-hundred day moving average of $81.33.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same period in the prior year, the business earned $0.75 earnings per share. The company’s quarterly revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, research analysts predict that Boston Scientific will post 3.38 EPS for the current fiscal year.

Boston Scientific declared that its Board of Directors has authorized a share repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its stock is undervalued.

Institutional Investors Weigh In On Boston Scientific

Hedge funds and other institutional investors have recently made changes to their positions in the business. Murphy & Mullick Capital Management Corp lifted its position in Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 170 shares during the period. FWL Investment Management LLC purchased a new stake in Boston Scientific in the 2nd quarter valued at about $26,000. Swiss RE Ltd. acquired a new position in shares of Boston Scientific during the 4th quarter valued at about $26,000. Garton & Associates Financial Advisors LLC acquired a new position in shares of Boston Scientific during the 4th quarter valued at about $26,000. Finally, United Community Bank lifted its holdings in shares of Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 147 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific announced a $2 billion accelerated share repurchase as part of its larger $5 billion buyback authorization, a move that can reduce share count and lift earnings per share over time. Boston Scientific enters into $2 billion accelerated share repurchase agreement
• Positive Sentiment: The company also invested $1.5 billion for about a 34% stake in MiRus, gaining an exclusive option to acquire MiRus’ TAVR business later if milestones are met. That gives Boston Scientific a potential pathway into the fast-growing structural heart market. Boston Scientific announces strategic investment in MiRus LLC
• Positive Sentiment: Late-breaking trial data for the SEISMIQ™ 4CE coronary intravascular lithotripsy catheter met primary safety and effectiveness endpoints in the FRACTURE IDE study, which could support future adoption and commercialization in calcified coronary artery disease. FRACTURE IDE trial of the Boston Scientific SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
• Neutral Sentiment: Wall Street analyst coverage remained favorable overall, with Needham and BTIG reiterating buy ratings, though Bank of America lowered its price target to $68 from $105. The mixed target action may temper some enthusiasm but still reflects bullish views on the stock. Boston Scientific Price Target Lowered to 68.00 at Bank of America

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.